美国在减肥药物使用率上领先;仿制司美格鲁肽可能在2026年底售价为每月3美元，实现全球可及。 U.S. leads in weight-loss drug use; generic semaglutide may cost $3/month by late 2026, enabling global access.

在诺沃·诺迪斯克(Novo Nordisk)的Wegovy推动下,美国在全球的减重药物使用中领先,诺沃·诺迪斯克(Novo Nordisk)的Wegovy为肥胖症注射了高剂量的微硫酸盐。 The U.S. leads globally in weight-loss drug use, driven by Novo Nordisk’s Wegovy, a high-dose semaglutide injection for obesity. 由于专利在2026年3月底到期,可以每月仅生产3美元,使肥胖症和糖尿病发病率不断上升的低收入和中等收入国家的数百万人能够获得这种药品。 As patents expire in late March 2026, semaglutide could be produced for just $3 per month, potentially enabling access for millions in low- and middle-income countries where obesity and diabetes rates are rising. 虽然该药物目前在美国的价格约为每月200美元左右,但印度、中国、巴西和墨西哥等国家可以提供通用版本,另外150个国家没有专利申请。 While the drug is currently priced at around $200 monthly in the U.S., generic versions could become available in nations like India, China, Brazil, and Mexico, with no patents filed in 150 other countries. 专家们说,负担得起的获取取决于政策变化、许可协议和全球协调,以克服监管基础设施和定价决定等障碍。 Experts say affordable access depends on policy changes, licensing agreements, and global coordination to overcome barriers like regulatory infrastructure and pricing decisions.